Global Pulmonary Function Testing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Type;
Complete PFT Systems and Portable PFT SystemsBy Test Type;
Spirometry , Lung Volume, Gas Exchange Testing, Maximal Voluntary Ventilation, Oxygen Titration Test, and High Altitude Simulation TestingBy Component;
Software, Hardware, and ServicesBy Application;
Chronic Obstructive Pulmonary Disease, Asthma, Chronic Shortness Of Breath, and Restrictive Lung DiseaseBy End User;
Hospital/Clinical Laboratories and Diagnostics LaboratoriesBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Pulmonary Function Testing Market Overview
Pulmonary Function Testing Market (USD Million)
Pulmonary Function Testing Market was valued at USD 594.87 million in the year 2024. The size of this market is expected to increase to USD 923.13 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.5%.
Global Pulmonary Function Testing Market Growth, Share, Size, Trends and Forecast
*Market size in USD million
CAGR 6.5 %
Study Period | 2025 - 2031 |
---|---|
Base Year | 2024 |
CAGR (%) | 6.5 % |
Market Size (2024) | USD 594.87 Million |
Market Size (2031) | USD 923.13 Million |
Market Concentration | Medium |
Report Pages | 358 |
Major Players
- COSMED Srl
- Vyaire Medical, Inc
- Medical Equipment Europe GmbH
- Medical Electronic Construction
- ECO MEDICS AG
- CHEST M.I., Inc
- MGC Diagnostic Corporation
- Medical Technologies.
- Schiller AG
- Hocoma
- NSPIRE HEALTH INC.
- ndd Medizintechnik AG
- Morgan Scientific Inc.
- Ganshorn Medizin Electronic
- Minato Holdings Inc.
- Koninklijke Philips N.V.
- Omron Healthcare, Inc.
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Global Pulmonary Function Testing Market
Fragmented - Highly competitive market without dominant players
The Pulmonary Function Testing (PFT) Market is witnessing substantial growth, primarily driven by the rising incidence of respiratory disorders. Chronic conditions like chronic obstructive pulmonary disease (COPD) and asthma account for nearly 60% of the overall demand for PFT systems. This surge is linked to escalating pollution levels and smoking rates, which collectively heighten the global respiratory disease burden.
Technological Innovations in Diagnostic Systems
Advancements in diagnostic technology are transforming pulmonary function testing. Modern PFT systems now deliver results 30% faster and with greater accuracy compared to traditional methods, supporting early disease detection and personalized treatment plans. This technological progress is crucial for enhancing patient outcomes and improving clinical decision-making.
Enhanced Patient Experience and Compliance
Modern PFT systems are increasingly designed for patient comfort and ease of use, resulting in higher compliance rates. Approximately 50% of these systems now feature user-friendly interfaces and automated data processing, reducing assessment time and improving the overall patient experience.
Growing Adoption in Homecare Settings
The adoption of portable PFT devices in homecare settings is expanding, representing nearly 25% of the market. This trend is driven by the need for continuous patient monitoring and personalized care, enhancing long-term health outcomes and supporting better disease management.
Pulmonary Function Testing Market Recent Developments
-
In March 2023 Vitalograph, a respiratory diagnostic devices manufacturer, announced the launch of the VitaloPFT Pulmonary Function Testing Series at the annual Arab Health Exhibition in Dubai. The product was launched with an aim for use in secondary care.
-
In March 2023 Vitalograph partnered with Morgan Scientific to launch a new range of pulmonary function testing (PFT) systems. Jointly, the partnership integrates advanced comprehensive PFT software from Morgan Scientific with PFT hardware from Vitalograph.
Pulmonary Function Testing Market Segment Analysis
In this report, the Pulmonary Function Testing Market has been segmented by Type, Test Type, Component, Application, End User and Geography.
Pulmonary Function Testing Market, Segmentation by Type
The Pulmonary Function Testing Market has been segmented by Type into Complete PFT Systems and Portable PFT Systems.
Complete PFT Systems
Complete Pulmonary Function Testing (PFT) systems are widely used in hospitals and diagnostic centers for comprehensive lung function testing. These systems are designed to assess all aspects of pulmonary health, including lung volumes, airflow, and gas exchange. Complete PFT systems account for approximately 70% of the market, due to their extensive diagnostic capabilities and high accuracy in chronic respiratory disease management.
Portable PFT Systems
Portable Pulmonary Function Testing (PFT) systems are gaining popularity due to their convenience and ease of use in both clinical and home care settings. These systems are typically smaller and more mobile, allowing for testing in various environments outside of traditional healthcare facilities. Portable PFT systems make up around 30% of the market, as they are increasingly preferred for their flexibility and ability to conduct screening in remote or underserved areas.
Pulmonary Function Testing Market, Segmentation by Test Type
The Pulmonary Function Testing Market has been segmented by Test Type into Spirometry , Lung Volume, Gas Exchange Testing, Maximal Voluntary Ventilation, Oxygen Titration Test, and High Altitude Simulation Testing.
Spirometry
Spirometry is the most commonly performed pulmonary function test, used to measure lung capacity and airflow obstruction. It is essential for diagnosing conditions such as asthma, COPD, and other respiratory disorders. Spirometry holds the largest market share of approximately 40% due to its widespread application in both clinical and primary care settings.
Lung Volume
Lung volume tests evaluate the total capacity of the lungs and identify restrictive lung diseases. These tests are critical in differentiating between obstructive and restrictive patterns of lung function. Lung volume testing accounts for around 20% of the market, particularly in hospitals and specialty pulmonary clinics.
Gas Exchange Testing
Gas exchange testing assesses the efficiency of oxygen and carbon dioxide transfer in the lungs. This test is vital in evaluating the severity of diseases like pulmonary fibrosis and interstitial lung disease. It contributes to about 15% of the market and is frequently used in conjunction with other tests for comprehensive evaluation.
Maximal Voluntary Ventilation
Maximal voluntary ventilation measures the greatest amount of air that can be inhaled and exhaled within a specific period. It is used to assess respiratory muscle strength and endurance, especially in patients with neuromuscular disorders. This test comprises roughly 10% of the total market.
Oxygen Titration Test
The oxygen titration test determines the optimal level of supplemental oxygen required by a patient during activity or sleep. It is particularly useful in managing patients with chronic hypoxemia or lung disease. This test type accounts for approximately 10% of the market.
High Altitude Simulation Testing
High altitude simulation testing evaluates how a patient's lungs respond to reduced oxygen levels, simulating high-altitude conditions. It is important for patients planning air travel or high-altitude exposure. This niche test makes up around 5% of the overall market but is growing steadily with rising travel-related respiratory evaluations.
Pulmonary Function Testing Market, Segmentation by Component
The Pulmonary Function Testing Market has been segmented by Component into Software, Hardware, and Services.
Software
Software plays a crucial role in modern pulmonary function testing by enabling precise data analysis, report generation, and remote monitoring. Advanced software solutions support real-time integration with electronic medical records and improve diagnostic accuracy. The software segment accounts for approximately 25% of the total market and continues to grow with digital healthcare adoption.
Hardware
Hardware includes the core diagnostic equipment such as spirometers, body plethysmographs, and gas analyzers. It represents the largest share—around 55%—of the market, driven by the rising demand for advanced and portable diagnostic devices across hospitals and diagnostic labs.
Services
Services include maintenance, calibration, training, and consultation offerings provided by manufacturers and third-party vendors. This segment accounts for roughly 20% of the market and is gaining importance as healthcare providers seek reliable, long-term support for pulmonary function testing systems.
Pulmonary Function Testing Market, Segmentation by Application
The Pulmonary Function Testing Market has been segmented by Application into Chronic Obstructive Pulmonary Disease, Asthma, Chronic Shortness Of Breath, and Restrictive Lung Disease.
Chronic Obstructive Pulmonary Disease
Pulmonary function testing is a cornerstone in diagnosing and managing Chronic Obstructive Pulmonary Disease (COPD), helping evaluate the extent of airflow limitation. With the global rise in smoking and pollution-related respiratory issues, this application accounts for approximately 45% of the total market share.
Asthma
In the management of asthma, pulmonary function tests like spirometry are critical for measuring airway responsiveness and monitoring treatment effectiveness. Asthma-related testing represents around 30% of the application market, driven by increasing asthma prevalence worldwide.
Chronic Shortness Of Breath
Pulmonary function testing is essential for patients presenting with chronic dyspnea or unexplained shortness of breath. These tests help distinguish between cardiac and pulmonary causes, contributing to about 15% of the total market.
Restrictive Lung Disease
Restrictive lung diseases, including pulmonary fibrosis and interstitial lung disease, require detailed lung volume measurements and gas exchange evaluations. This segment holds approximately 10% of the market and is expected to grow due to rising cases of post-COVID pulmonary complications.
Pulmonary Function Testing Market, Segmentation by End User
The Pulmonary Function Testing Market has been segmented by End User into Hospital/Clinical Laboratories, and Diagnostics Laboratories.
Hospital/Clinical Laboratories
Hospital and clinical laboratories are the primary end users of pulmonary function testing systems, accounting for approximately 65% of the market. These facilities utilize comprehensive diagnostic tools to assess patients with chronic respiratory diseases such as COPD and asthma, often integrating results into electronic health records for efficient care management.
Diagnostics Laboratories
Diagnostic laboratories represent a growing share—about 35%—of the market, driven by increasing referrals for specialized respiratory testing and outsourced diagnostic services. These labs often offer a range of pulmonary tests including spirometry, gas exchange analysis, and lung volume measurements to support early and accurate disease detection.
Pulmonary Function Testing Market, Segmentation by Geography
In this report, the Pulmonary Function Testing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa and Latin America.
Regions and Countries Analyzed in this Report
Pulmonary Function Testing Market Share (%), by Geographical Region
North America
North America leads the pulmonary function testing market, contributing to over 35% of the global share. The region’s dominance is driven by high prevalence of chronic respiratory diseases, advanced healthcare infrastructure, and widespread adoption of digital diagnostic solutions.
Europe
Europe holds a significant share of around 25%, supported by strong government initiatives for early diagnosis and chronic disease management. Countries like Germany, the UK, and France are key contributors, with increasing investment in lung health screening programs.
Asia Pacific
The Asia Pacific region is emerging as a fast-growing market, accounting for nearly 20%. Factors such as a rising burden of air pollution-related illnesses, growing healthcare access, and expanding medical device industry contribute to the region’s growth, especially in China, India, and Japan.
Middle East & Africa
Middle East & Africa collectively make up about 10% of the market, with growth supported by increasing awareness of pulmonary health and expanding healthcare infrastructure in urban centers.
Latin America
Latin America accounts for roughly 10% of the market. Brazil and Mexico lead the region due to growing demand for advanced diagnostic equipment and government efforts to enhance respiratory care services.
Pulmonary Function Testing Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Pulmonary Function Testing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces—Drivers, Restraints, and Opportunities—affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
---|---|---|---|---|---|
Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers :
- Increasing Prevalence of Respiratory Diseases
- Growing Emphasis on Preventive Healthcare
-
Rising Awareness of Lung Health - The pulmonary function testing market is expanding steadily, supported by growing awareness of lung health across diverse populations. As respiratory conditions such as asthma, COPD, and post-infectious lung complications become more prevalent, both patients and healthcare providers are placing greater emphasis on early detection and routine monitoring. This shift in mindset is encouraging the wider adoption of pulmonary function tests as essential tools for evaluating respiratory performance and identifying functional impairments at early stages.
Health campaigns, educational programs, and broader public discourse are significantly influencing this trend by promoting the importance of preventive lung care. Individuals are increasingly aware of the negative impact of smoking, environmental pollutants, and occupational hazards on their respiratory system. As a result, demand is rising for routine lung assessments, especially among at-risk populations. Healthcare facilities are now incorporating pulmonary testing into standard clinical workflows to support timely diagnosis and improve long-term respiratory outcomes.
The aftermath of the COVID-19 pandemic has further intensified the focus on respiratory health. With long-term lung function monitoring becoming a priority in post-COVID care, pulmonary function testing is now seen as a critical component of patient evaluation and recovery management. Hospitals and rehabilitation centers have increased investments in spirometry and related testing equipment to address both acute respiratory needs and chronic pulmonary complications stemming from viral infections.
In response to the surge in demand, manufacturers are developing more portable, digital, and user-friendly pulmonary function testing devices that can be used in various clinical and home settings. These advancements are making respiratory screening more accessible, especially in primary care and remote health facilities. As awareness continues to rise and technology becomes more integrated into routine care, the pulmonary function testing market is poised for sustained growth through improved detection, broader outreach, and personalized respiratory health strategies.
Restraints:
- High Cost of Advanced Testing Equipment
- Lack of Trained Professionals in Some Regions
-
Limitations of Traditional Testing Methods - Posing a considerable challenge to the growth of the pulmonary function testing market. Standard diagnostic tools like spirometry and peak flow meters, although commonly used, often lack the sensitivity and depth required to detect subtle or early-stage pulmonary conditions. These methods may not provide a full picture of lung function, making it difficult to differentiate between complex or overlapping respiratory disorders. This can result in delayed diagnosis, inappropriate therapy selection, and ultimately, poorer patient outcomes.
A major drawback of traditional pulmonary tests is their dependence on patient effort and technique. Accurate spirometry readings rely heavily on the patient's ability to perform forced breathing maneuvers correctly, which can be challenging for young children, elderly individuals, or patients with physical or cognitive impairments. Inconsistencies in technique can lead to unreliable data, increasing the need for repeat testing and complicating clinical decision-making for healthcare providers.
Another concern is the technological limitations of older testing devices. Many traditional methods are not equipped for real-time data analysis or integration with digital health records. They often produce isolated, static results rather than continuous or dynamic lung function monitoring. This lack of connectivity and adaptability makes it harder to apply these tools within modern healthcare frameworks focused on long-term disease tracking and personalized treatment plans.
As healthcare systems evolve toward precision medicine and digital integration, the shortcomings of outdated pulmonary testing methods are becoming more evident. The absence of comprehensive data, combined with operational inefficiencies, restricts their utility in managing chronic respiratory conditions. Unless these limitations are addressed through technological advancement or replacement with next-generation tools, traditional testing methods will continue to constrain the diagnostic potential and market growth of pulmonary function testing solutions.
Opportunities:
- Development of Portable and User-Friendly Devices
- Growing Public Health Initiatives Promoting Lung Health
-
Expansion in Emerging Markets - The growing focus on emerging markets is driving significant opportunities in the pulmonary function testing market. As awareness of respiratory health increases in low- and middle-income countries, so does the demand for reliable lung function diagnostics. With conditions like asthma, COPD, and post-COVID complications on the rise, healthcare systems in these regions are making early diagnosis and routine screening a priority.
Rapid urbanization, industrial growth, and increased exposure to air pollutants have led to a higher prevalence of respiratory illnesses. These trends have underscored the need for regular pulmonary assessments in both community clinics and mobile health units. The integration of lung function testing into preventive health programs is proving essential in addressing the growing burden of chronic respiratory diseases in these markets.
Global manufacturers are actively expanding into these regions by establishing strategic partnerships and local distribution channels. The development of cost-effective and portable testing devices is enabling broader access to diagnostics in resource-limited areas. Additionally, advancements in digital connectivity and telemedicine are facilitating remote respiratory care, making it possible for patients in rural communities to receive timely assessments.
International support from health organizations and government initiatives is further propelling this growth. Funding for training programs, public awareness campaigns, and infrastructure improvements is equipping healthcare providers with the necessary tools for effective pulmonary care. As these efforts continue, emerging markets are expected to become a key driver for sustained expansion in the pulmonary function testing space.
Pulmonary Function Testing Market Competitive Landscape Analysis
Key players in Pulmonary Function Testing Market include,
- COSMED Srl
- Vyaire Medical, Inc
- Medical Equipment Europe GmbH
- Medical Electronic Construction
- ECO MEDICS AG
- CHEST M.I., Inc
- MGC Diagnostic Corporation
- Medical Technologies.
- Schiller AG
- Hocoma
- NSPIRE HEALTH INC.
- ndd Medizintechnik AG
- Morgan Scientific Inc.
- Ganshorn Medizin Electronic
- Minato Holdings Inc.
- Koninklijke Philips N.V.
- Omron Healthcare, Inc.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Market Share Analysis
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Test Type
- Market Snapshot, By Component
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Pulmonary Function Testing Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Increasing Prevalence of Respiratory Diseases
-
Growing Emphasis on Preventive Healthcare
-
Rising Awareness of Lung Health
-
- Restraints
-
High Cost of Advanced Testing Equipment
-
Lack of Trained Professionals in Some Regions
-
Limitations of Traditional Testing Methods
-
- Opportunities
-
Development of Portable and User-Friendly Devices
-
Growing Public Health Initiatives Promoting Lung Health
-
Expansion in Emerging Markets
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Pulmonary Function Testing Market, By Type, 2021 - 2031 (USD Million)
- Complete PFT Systems
- Portable PFT Systems
- Pulmonary Function Testing Market, By Test Type, 2021 - 2031 (USD Million)
- Spirometry
- Lung Volume
- Gas Exchange Testing
- Maximal Voluntary Ventilation
- Oxygen Titration Test
- High Altitude Simulation Testing
- Pulmonary Function Testing Market, By Component, 2021 - 2031 (USD Million)
- Software
- Hardware
- Services
- Pulmonary Function Testing Market, By Application, 2021- 2031(USD Million)
- Chronic Obstructive Pulmonary Disease
- Asthma
- Chronic Shortness Of Breath
- and Restrictive Lung Disease
- Pulmonary Function Testing Market, By End User, 2021 - 2031(USD Million)
- Hospital/Clinical Laboratories
- Diagnostics Laboratories
- Pulmonary Function Testing Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Pulmonary Function Testing Market, By Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- COSMED Srl
- Vyaire Medical, Inc
- Medical Equipment Europe GmbH
- Medical Electronic Construction
- ECO MEDICS AG
- CHEST M.I., Inc
- MGC Diagnostic Corporation
- Medical Technologies.
- Schiller AG
- Hocoma
- NSPIRE HEALTH INC.
- ndd Medizintechnik AG
- Morgan Scientific Inc.
- Ganshorn Medizin Electronic
- Minato Holdings Inc.
- Koninklijke Philips N.V.
- Omron Healthcare, Inc.
- Company Profiles
- Analyst Views
- Future Outlook of the Market